Ambiotis develops and validates models and technologies to bring proofs of concept and decipher mechanisms of action of molecules for its customers. It helps its business partners put faster on the market new and innovative compounds from early preclinical stages up to clinical assays. Ambiotis was created in 2007 as a Young and Innovative Start-up and has been the first CRO worldwide working on the active resolution of inflammation. More than 50% of the activity is invested in R&D to provide always cutting edge research services. Since its creation, Ambiotis has promoted the field of inflammation resolution, first discovered by Pr Charles Serhan at Harvard Medical School. Ambiotis has dedicated its research to this field to build a thorough experience, now worldwide recognized. A comprehensive chemical analysis service dedicated to the targeted identification and quantitation of biomolecules is deployed to meet the growing needs of our customers relative to the mechanism of action and proof of concept of their products in a given biological model. The most important service which is offer today is lipidomics. With this knowledge, Ambiotis aims now to be the perfect partner for preclinical and clinical research in the field.
Lipidomics, resolution, inflammation, skin lipids, sebum lipids, ceramides, fatty acids, squalene, SPM, Resolvin,
Biochemistry & Molecular Biology Services
Liquid Chromatography Coupled Mass Spectrometry Methods Services
Gastroenterology Animal Models Services
AMBIOTIS SAS has not received any reviews.
AMBIOTIS SAS has not received any endorsements.